Related Experiment Videos

The importance of lost minerals in heart failure

Kevin P Newman1, Matthew T Neal, Matthew Roberts

  • 1Division of Cardiovascular Diseases, Department of Medicine, University of Tennessee Health Science Center, 920 Madison Ave., Suite 300, Memphis, TN 38163, USA. KNewman@utmem.edu

Cardiovascular & Hematological Agents in Medicinal Chemistry
|November 6, 2007
PubMed

Insights

Congestive heart failure (CHF) involves a salt-avid state and systemic illness. Mineral dyshomeostasis, particularly of Ca2+, Mg2+, Zn, and Se, significantly impacts CHF progression and associated oxidative stress and inflammation.

Area of Science:

  • Cardiovascular Medicine
  • Nutritional Science
  • Biochemistry

Background:

  • Congestive heart failure (CHF) is linked to a salt-avid state driven by the renin-angiotensin-aldosterone system (RAAS).
  • Chronic RAAS activation causes systemic illness, including oxidative stress, inflammation, and catabolism (cardiac cachexia).

Purpose of the Study:

  • To investigate the role of mineral dyshomeostasis (Ca2+, Mg2+, Zn, Se) in the progression of CHF.
  • To explore the impact of mineral imbalances on oxidative stress, antioxidant defenses, inflammation, and tissue wasting in CHF.
  • To assess the potential of nutraceuticals in managing CHF.

Main Methods:

  • The study reviews existing literature on the pathophysiology of CHF, focusing on hormonal and pharmacologic factors influencing mineral balance.
  • Analysis of the relationship between mineral dyshomeostasis and key features of CHF, such as oxidative stress and inflammation.
  • Exploration of the potential therapeutic role of nutraceuticals in CHF management.

Main Results:

  • Mineral dyshomeostasis (Ca2+, Mg2+, Zn, Se) is an underappreciated factor in the systemic and progressive nature of CHF.
  • Hormonal factors (aldosteronism, secondary hyperparathyroidism, hypovitaminosis D) and medications (diuretics, ACE inhibitors) contribute to mineral loss.
  • Imbalances in these minerals exacerbate oxidative stress, impair antioxidant defenses, promote inflammation, and contribute to tissue wasting.

Conclusions:

  • Mineral dyshomeostasis is a critical factor in CHF pathogenesis and progression.
  • Addressing mineral imbalances through nutritional interventions or nutraceuticals may complement pharmaceutical treatments for CHF.
  • Further research is needed to fully elucidate the role of minerals and the efficacy of nutraceuticals in CHF management.

Related Concept Videos

Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
Heart Failure VII: Nursing Interventions01:30

Heart Failure VII: Nursing Interventions

The first step in nursing management of a patient with heart failure involves thoroughly assessing the patient's medical history.Subjective Data: Obtain the patient's medical history of coronary artery disease, hypertension, myocardial infarction, and symptoms like dyspnea, orthopnea, and paroxysmal nocturnal dyspnea.Objective Data: Conduct a physical examination to identify findings such as jugular vein distention, pulmonary crackles, tachycardia, murmurs, peripheral edema, and vital signs,...
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Heart Failure I: Introduction01:27

Heart Failure I: Introduction

Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
Mitral Regurgitation IV: Nursing Management01:28

Mitral Regurgitation IV: Nursing Management

Mitral regurgitation (MR) is a condition where the mitral valve does not close properly, leading to the backward flow of blood from the left ventricle into the left atrium during systole. This condition can arise from various causes, including rheumatic fever, infective endocarditis, or degenerative valve disease. Effective nursing management is crucial to optimizing patient outcomes and involves comprehensive assessment and targeted interventions.Comprehensive Patient AssessmentA detailed...